ATHE Alterity Therapeutics Ltd - ADR
8,846
$2.10
$0.0001
(0.01%)
| Watchers | 8,846 |
| 52-Wk Low | $1.55 |
| 52-Wk High | $5.41 |
| Market Cap | $18.1M |
| Volume | 5,201.00 |
| 52-Wk High | $5.41 |
| 52-Wk Low | $1.55 |
Alterity Therapeutics receives A$3.9M R&D Tax Incentive refundThe Fly • about 2 months ago
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Share to Feed
MELBOURNE, AustraliaandSAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ( Alterity or the Company ), a biotechnology company...
Alterity Therapeutics Limited (NASDAQ:ATHE Get Free Report) saw a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 37,800...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease to be Presented at International Conference Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2...
- ATH434-201 Trial on Track to Complete in November 2024 - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Alterity...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ( Alterity or the Company ), a biotechnology company dedicated to...
Preliminary Data from ATH434-202 Study Expected in 1H 2024 ATH434-201 Study to Complete in November 2024 MELBOURNE, Australiaand SAN FRANCISCO, Jan. 22, 2024 (GLOBE NEWSWIRE...
Alterity Therapeutics Limited (NASDAQ:ATHE Get Free Report) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest...
Alterity Therapeutics (NASDAQ:ATHE Get Free Report) and Atea Pharmaceuticals (NASDAQ:AVIR Get Free Report) are both small-cap medical companies, but which is the superior investment...